MedPath

Ultrasound Guided Rectus Sheath Block Versus Intrathecal Morphine for Postoperative Analgesia in Patients Undergoing Open Total Abdominal Hysterectomy

Not Applicable
Recruiting
Conditions
Ultrasound
Postoperative Analgesia
Rectus Sheath Block
Intrathecal Morphine
Total Abdominal Hysterectomy
Interventions
Drug: Rectus sheath block
Registration Number
NCT06837506
Lead Sponsor
Ain Shams University
Brief Summary

This study aims to compare the effectiveness and safety of ultrasound-guided rectus sheath block versus intrathecal morphine for postoperative analgesia in patients undergoing open total abdominal hysterectomy.

Detailed Description

Effective postoperative analgesia is crucial for enhancing recovery and patient satisfaction following major surgical procedures, such as total abdominal hysterectomy (TAH).

Rectus sheath block (RSB), an ultrasound-guided regional anesthesia technique, involves the injection of local anesthetic into the rectus sheath, providing analgesia to the anterior abdominal wall. RSB is used to block the sensory nerves of the anterior abdominal wall and thereby contributing to pain relief after lower abdominal surgeries.

Intrathecal morphine (ITM) provides a highly effective method of analgesia by delivering the medication directly into the cerebrospinal fluid (CSF).

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
80
Inclusion Criteria
  • Age: 18 - 65 years old.
  • American Society of Anesthesiologists (ASA) physical status (I -II).
  • Patients undergoing open total abdominal hysterectomy.
Exclusion Criteria
  • Hepatic, renal, or cardiac disease.
  • Any known allergy to local anesthetic.
  • Physical or mental conditions which may vague measuring postoperative pain following surgery.
  • History of chronic use of analgesic as nonsteroidal anti-inflammatory drugs (NSAIDs) or central nervous system (CNS) depressants as antiepileptic, and bleeding disorders.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Rectus sheath block groupRectus sheath blockPatients will receive rectus sheath block (20 ml bilaterally, bupivacaine 0.25%) after induction of general anesthesia.
Intrathecal morphine groupIntrathecal morphinePatients will receive 150 µg intrathecal morphine after induction of general anesthesia.
Primary Outcome Measures
NameTimeMethod
Total morphine consumption24 hours postoperatively

Morphine will be administered if the visual analog scale (VAS) score is ≥ 4.

Secondary Outcome Measures
NameTimeMethod
Time to the first request for the rescue analgesia24 hours postoperatively

Time to the first request for the rescue analgesia (time from the end of surgery till first dose of morphine administrated)

Degree of pain24 hours postoperatively

Each patient will be instructed about postoperative pain assessment with the Visual Analogue Scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable"). VAS will be assessed after surgery over 24 hour using VAS scale at (post-anesthesia care unit, 2, 4, 6, 12, 18, and 24 h).

Degree of patient satisfaction24 hours postoperatively

The degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied).

Time of hospital discharge28 days postoperatively

Time of hospital discharge will be recorded from admission till the discharge from hospital.

Degree of sedationIntraoperatively

Sedation will be assessed using Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S): (5 Alert: Responds readily to name spoken in normal tone, 4: Lethargic response to name spoken in normal tone, 3: Responds only after name is called loudly and/or repeatedly, 2: Responds only after mild prodding or shaking ,1: Responds only after painful trapezius squeeze,0: Does not respond to painful trapezius squeeze).

Incidence of adverse events24 hours postoperatively

Incidence of adverse events such as hematoma, nerve damage or neuropathy, bradycardia, hypotension, nausea, vomiting, pruritis, or any other complication will be recorded.

Trial Locations

Locations (1)

Ain Shams University

🇪🇬

Cairo, Egypt

Ain Shams University
🇪🇬Cairo, Egypt
Sarah A Afifi, MD
Contact
0501035864
Sarah606060@gmail.com
Sondos Afifi, MD
Principal Investigator
Ahmed M Eldemerdash, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.